GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005165617 | Esophagus | ESCC | establishment of organelle localization | 273/8552 | 390/18723 | 9.13e-23 | 1.81e-20 | 273 |
GO:1904951111 | Esophagus | ESCC | positive regulation of establishment of protein localization | 216/8552 | 319/18723 | 1.01e-15 | 6.86e-14 | 216 |
GO:0051222111 | Esophagus | ESCC | positive regulation of protein transport | 204/8552 | 303/18723 | 1.56e-14 | 8.38e-13 | 204 |
GO:001648210 | Esophagus | ESCC | cytosolic transport | 124/8552 | 168/18723 | 9.69e-14 | 4.69e-12 | 124 |
GO:005165016 | Esophagus | ESCC | establishment of vesicle localization | 114/8552 | 161/18723 | 8.20e-11 | 2.53e-09 | 114 |
GO:003070518 | Esophagus | ESCC | cytoskeleton-dependent intracellular transport | 133/8552 | 195/18723 | 1.48e-10 | 4.27e-09 | 133 |
GO:001097013 | Esophagus | ESCC | transport along microtubule | 107/8552 | 155/18723 | 3.17e-09 | 6.80e-08 | 107 |
GO:005164815 | Esophagus | ESCC | vesicle localization | 119/8552 | 177/18723 | 5.16e-09 | 1.08e-07 | 119 |
GO:00723846 | Esophagus | ESCC | organelle transport along microtubule | 65/8552 | 85/18723 | 6.61e-09 | 1.35e-07 | 65 |
GO:000808810 | Esophagus | ESCC | axo-dendritic transport | 58/8552 | 75/18723 | 2.09e-08 | 4.02e-07 | 58 |
GO:00989304 | Esophagus | ESCC | axonal transport | 49/8552 | 64/18723 | 4.54e-07 | 6.15e-06 | 49 |
GO:00474962 | Esophagus | ESCC | vesicle transport along microtubule | 36/8552 | 47/18723 | 1.53e-05 | 1.38e-04 | 36 |
GO:00991114 | Esophagus | ESCC | microtubule-based transport | 115/8552 | 190/18723 | 2.54e-05 | 2.15e-04 | 115 |
GO:00080892 | Esophagus | ESCC | anterograde axonal transport | 37/8552 | 50/18723 | 4.42e-05 | 3.51e-04 | 37 |
GO:005165411 | Esophagus | ESCC | establishment of mitochondrion localization | 24/8552 | 29/18723 | 4.50e-05 | 3.55e-04 | 24 |
GO:00995185 | Esophagus | ESCC | vesicle cytoskeletal trafficking | 50/8552 | 73/18723 | 6.75e-05 | 5.12e-04 | 50 |
GO:00346431 | Esophagus | ESCC | establishment of mitochondrion localization, microtubule-mediated | 21/8552 | 26/18723 | 2.69e-04 | 1.63e-03 | 21 |
GO:00474971 | Esophagus | ESCC | mitochondrion transport along microtubule | 21/8552 | 26/18723 | 2.69e-04 | 1.63e-03 | 21 |
GO:00516463 | Esophagus | ESCC | mitochondrion localization | 35/8552 | 50/18723 | 4.33e-04 | 2.44e-03 | 35 |
GO:000930617 | Esophagus | ESCC | protein secretion | 190/8552 | 359/18723 | 3.22e-03 | 1.34e-02 | 190 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SYBU | SNV | Missense_Mutation | | c.563N>G | p.Ser188Trp | p.S188W | Q9NX95 | protein_coding | tolerated(0.08) | probably_damaging(0.985) | TCGA-A2-A04T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
SYBU | SNV | Missense_Mutation | | c.1075T>G | p.Phe359Val | p.F359V | Q9NX95 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A2-A0D3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
SYBU | SNV | Missense_Mutation | | c.171N>A | p.Phe57Leu | p.F57L | Q9NX95 | protein_coding | tolerated(0.15) | possibly_damaging(0.84) | TCGA-A2-A0T3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
SYBU | SNV | Missense_Mutation | | c.1928N>G | p.Leu643Arg | p.L643R | Q9NX95 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
SYBU | SNV | Missense_Mutation | | c.1081G>A | p.Asp361Asn | p.D361N | Q9NX95 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AC-A23C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | chemo | CR |
SYBU | SNV | Missense_Mutation | | c.287C>T | p.Ala96Val | p.A96V | Q9NX95 | protein_coding | deleterious(0.01) | benign(0.254) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SYBU | SNV | Missense_Mutation | | c.1250N>G | p.Glu417Gly | p.E417G | Q9NX95 | protein_coding | tolerated(0.37) | possibly_damaging(0.74) | TCGA-AR-A0TV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SYBU | SNV | Missense_Mutation | | c.1330N>A | p.Glu444Lys | p.E444K | Q9NX95 | protein_coding | tolerated(0.17) | benign(0.443) | TCGA-B6-A0WZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
SYBU | SNV | Missense_Mutation | | c.84N>C | p.Leu28Phe | p.L28F | Q9NX95 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
SYBU | SNV | Missense_Mutation | | c.1427N>A | p.Gly476Asp | p.G476D | Q9NX95 | protein_coding | tolerated(0.38) | benign(0) | TCGA-E2-A159-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |